AFM 13

Drug Profile

AFM 13

Alternative Names: AFM-13; Anti CD30 x anti CD16; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; TandAb AFM13

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Merck AG; The Leukemia & Lymphoma Society; University of Cologne; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD30 antigen modulators; Fc gamma receptor IIIA modulators; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hodgkin's disease
  • Phase I/II Lymphoma
  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Jun 2018 Updated efficacy data from phase I trial in Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) presented at the 23rd Congress of European Hematology Association (EHA-2018)
  • 01 Mar 2018 Affimed Therapeutics has patent protection for the use of the specific target combination for the treatment of cancer, using AFM 13, in Austria, Belgium, France, Germany, Great Britain, Ireland, Italy, the Netherlands, Spain, Switzerland and Liechtenstein
  • 01 Feb 2018 Interim efficacy data from phase I trial in Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) released by Affimed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top